Integrative omics approach identifies interleukin-16 as a biomarker of emphysema

OMICS A Journal of Integrative Biology

Volumn 17, Issue 12, 2013, Pages 619-626

  Bowler, Russell P ^a   Bahr, Timothy M ^b   Hughes, Grant ^b   Lutz, Sharon ^b   Kim, Yu Il ^c   Coldren, Christopher D ^d   Reisdorph, Nichole ^a   Kechris, Katerina J ^b  

^a DEPARTMENT OF MEDICINE   (United States)

^b Department of Civil and Environmental Engineering at Colorado State University and the Department of Environmental and Occupational Health at the Colorado School of Public Health   (United States)

^c Chonnam National University   (South Korea)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FRESH FROZEN PLASMA; INTERLEUKIN 16; MESSENGER RNA;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; EMPHYSEMA; FEMALE; GENE EXPRESSION; HUMAN; LUNG LOBE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE TRAIT LOCUS; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ADRENAL CORTEX HORMONES; AGED; BIOLOGICAL MARKERS; EMPHYSEMA; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-16; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEOMICS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUANTITATIVE TRAIT LOCI; SMOKING;

EID: 84888229847     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2013.0038     Document Type: Article

References (50)

1. Akesson LS, Duffy DL, Phelps SC, Thompson PJ, and Kedda MA. (2005). A polymorphism in the promoter region of the human interleukin-16 gene is not associated with asthma or atopy in an Australian population. Clin Exp Allergy 35, 327-331.
2. Akiyama K, Karaki M, Kobayshi R, Dobashi H, Ishida T, and Mori N. (2009). IL-16 variability and modulation by antiallergic drugs in a murine experimental allergic rhinitis model. Int Arch Allergy Immunol 149, 315-322.
3. Andersson A, Qvarfordt I, Laan M, et al. (2004). Impact of tobacco smoke on interleukin-16 protein in human airways, lymphoid tissue and T lymphocytes. Clin Exp Immunol 138, 75-82.
4. Bahr TM, Hughes GJ, Armstrong A, et al. (2013). Peripheral blood mononuclear cell gene expression in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 49, 316-323.
5. Baier M, Bannert N, Werner A, Lang K, and Kurth R. (1997). Molecular cloning, sequence, expression, and processing of the interleukin-16 precursor. Proc Natl Acad Sci USA 94, 5273-5277.
6. Barnes PJ. (2006). Against the Dutch hypothesis: Asthma and chronic obstructive pulmonary disease are distinct diseases. Am J Respir Crit Care Med 174, 240-243; discussion 243-244.
7. Blaschke S, Schulz H, Schwarz G, Blaschke V, Muller GA, and Reuss-Borst M. (2001). Interleukin-16 expression in relation to disease activity in rheumatoid arthritis. J Rheumatol 28, 12-21.
8. Bolstad BM, Irizarry RA, Astrand M, and Speed TP. (2003). A comparison ofnormalizationmethods forhighdensity oligonucleotide array data based on variance and bias. Bioinformatics 19, 185-193.
9. Bowler RP, Barnes PJ, and Crapo JD. (2004). The role of oxidative stress in chronic obstructive pulmonary disease. Copd 1, 255-277.
10. Burkart KM, Barton SJ, Holloway JW, et al. (2006). Association of asthma with a functional promoter polymorphism in the IL16 gene. J Allergy Clin Immunol 117, 86-91.
11. Cho MH, Castaldi PJ, Wan ES, et al. (2012). A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet 21, 947-957.
12. Cruikshank WW, Kornfeld H, and Center DM. (2000). Interleukin-16. J Leukoc Biol 67, 757-766.
13. Cruikshank WW, Long A, Tarpy RE, et al. (1995). Early identification of interleukin-16 (lymphocyte chemoattractant factor) and macrophage inflammatory protein 1 alpha (MIP1 alpha) in bronchoalveolar lavage fluid of antigen-challenged asthmatics. Am J Respir Cell Mol Biol 13, 738-747.
14. de Torres JP, Casanova C, Pinto-Plata V, et al. (2011). Gender differences in plasma biomarker levels in a cohort of COPD patients: A pilot study. PLoS ONE 6, e16021.
15. Duan H, Fleming J, Pritchard DK, et al. (2008). Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum 58, 1465-1474.
16. El Bassam S, Pinsonneault S, Kornfeld H, Ren F, Menezes J, and Laberge S. (2006). Interleukin-16 inhibits interleukin-13 production by allergen-stimulated blood mononuclear cells. Immunology 117, 89-96.
17. Fabbri LM, and Hurd SS. (2003). Global strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur Respir J 22, 1-2.
18. Ferland C, Flamand N, Davoine F, Chakir J, and Laviolette M. (2004). IL-16 activates plasminogen-plasmin system and promotes human eosinophil migration into extracellular matrix via CCR3-chemokine-mediated signaling and by modulating CD4 eosinophil expression. J Immunol 173, 4417-4424.
19. Frezzolini A, Cianchini G, Ruffelli M, Cadoni S, Puddu P, and De Pita O. (2004). Interleukin-16 expression and release in bullous pemphigoid. Clin Exp Immunol 137, 595-600.
20. Gao LB, Rao L, Wang YY, et al. (2009). The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer. Carcinogenesis 30, 295-299.
21. Ghigo E, Barry AO, Pretat L, et al. (2010). IL-16 promotes T. whipplei replication by inhibiting phagosome conversion and modulating macrophage activation. PLoS One 5, e13561.
22. Goihl A, Rolle AM, Kahne T, Reinhold A, Wrenger S, and Reinhold D. (2012). Methodologic issues in the measurement of interleukin-16 in clinical blood samples using immunoassays. Cytokine 58, 1-5.
23. Gu Y, Lewis SF, Deere K, Groome LJ, and Wang Y. (2008). Elevated maternal IL-16 levels, enhanced IL-16 expressions in endothelium and leukocytes, and increased IL-16 production by placental trophoblasts in women with preeclampsia. J Immunol 181, 4418-4422.
24. Hankinson JL, Odencrantz JR, and Fedan KB. (1999). Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 159, 179-187.
25. Jin CZ, Zhao Y, Zhang FJ, et al. (2009). Different plasma levels of interleukins and chemokines: Comparison between children and adults with AIDS in China. Chin Med J (Engl) 122, 530-535.
26. Kaser A, Dunzendorfer S, Offner FA, et al. (2000). B lymphocytederived IL-16 attracts dendritic cells and Th cells. J Immunol 165, 2474-2480.
27. Kaufmann J, Franke S, Kientsch-Engel R, Oelzner P, Hein G, and Stein G. (2001). Correlation of circulating interleukin-16 with proinflammatory cytokines in patients with rheumatoid arthritis. Rheumatology (Oxford) 40, 474-475.
28. Kim YI, Schroeder J, Lynch D, et al. (2011). Gender differences of airway dimensions in anatomically matched sites on CT in smokers. COPD 8, 285-292.
29. Klimiuk PA, Goronzy JJ, and Weyand CM. (1999). IL-16 as an anti-inflammatory cytokine in rheumatoid synovitis. J Immunol 162, 4293-4299.
30. Krug N, Cruikshank WW, Tschernig T, et al. (2000). Interleukin-16 and T-cell chemoattractant activity in bronchoalveolar lavage 24 hours after allergen challenge in asthma. Am J Respir Crit Care Med 162, 105-111.
31. Laberge S, Ernst P, Ghaffar O, et al. (1997). Increased expression of interleukin-16 in bronchial mucosa of subjects with atopic asthma. Am J Respir Cell Mol Biol 17, 193-202.
32. Laberge S, Ghaffar O, Boguniewicz M, Center DM, Leung DY, and Hamid Q. (1998). Association of increased CD4 + T-cell infiltration with increased IL-16 gene expression in atopic dermatitis. J Allergy Clin Immunol 102, 645-650.
33. Lard LR, Roep BO, Toes RE, and Huizinga TW. (2004). Enhanced concentrations of interleukin-16 are associated with joint destruction in patients with rheumatoid arthritis. J Rheumatol 31, 35-39.
34. Lard LR, Roep BO, Verburgh CA, Zwinderman AH, and Huizinga TW. (2002). Elevated IL-16 levels in patients with systemic lupus erythematosus are associated with disease severity but not with genetic susceptibility to lupus. Lupus 11, 181-185.
35. Lee S, Kaneko H, Sekigawa I, Tokano Y, Takasaki Y, and Hashimoto H. (1998). Circulating interleukin-16 in systemic lupus erythematosus. Br J Rheumatol 37, 1334-1337.
36. Lee SH, Goswami S, Grudo A, et al. (2007). Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 13, 567-569.
37. Livak KJ, and Schmittgen TD. (2001). Analysis of relative gene expression data using real-Time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25, 402-408.
38. Lokke A, Lange P, Scharling H, Fabricius P, and Vestbo J. (2006). Developing COPD: A 25 year follow up study of the general population. Thorax 61, 935-939.
39. Mar J, Kimura Y, Schroder K, et al. (2009). Data-driven normalization strategies for high-Throughput quantitative RTPCR. BMC Bioinformat 10, 110.
40. Mathy NL, Scheuer W, Lanzendorfer M, et al. (2000). Interleukin-16 stimulates the expression and production of proinflammatory cytokines by human monocytes. Immunology 100, 63-69.
41. McFadden C, Morgan R, Rahangdale S, et al. (2007). Preferential migration of T regulatory cells induced by IL-16. J Immunol 179, 6439-6445.
42. Meagher C, Beilke J, Arreaza G, et al. (2010). Neutralization of interleukin-16 protects nonobese diabetic mice from autoimmune type 1 diabetes by a CCL4-dependent mechanism. Diabetes 59, 2862-2871.
43. Motta M, Imbesi R, Di Rosa M, Stivala F, and Malaguarnera L. (2007). Altered plasma cytokine levels in Alzheimer's disease: Correlation with the disease progression. Immunol Lett 114, 46-51.
44. Packard TA, Li QZ, Cosgrove GP, Bowler RP, and Cambier JC. (2013). COPD is associated with production of autoantibodies to a broad spectrum of self-antigens, correlative with disease phenotype. Immunol Res 55, 48-57.
45. Pullerits T, Linden A, Malmhall C, and Lotvall J. (2001). Effect of seasonal allergen exposure on mucosal IL-16 and CD4 + cells in patients with allergic rhinitis. Allergy 56, 871-877.
46. Qi JC, Wang J, Mandadi S, et al. (2006). Human and mouse mast cells use the tetraspanin CD9 as an alternate interleukin-16 receptor. Blood 107, 135-142.
47. R Development Core Team (2008). R: A Language and Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing.
48. Regan EA, Hokanson JE, Murphy JR, et al. (2010). Genetic epidemiology of COPD (COPDGene) study design. COPD 7, 32-43.
49. Vandesompele J, De Preter K, Pattyn F, et al. (2002). Accurate normalization of real-Time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3, RESEARCH0034.
50. Zhang Y, Center DM, Wu DM, et al. (1998). Processing and activation of pro-interleukin-16 by caspase-3. J Biol Chem 273, 1144-1149.